. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7

Table 2.

Search terms for systematic literature review conducted 1st January 2019 until 19th July 2022.

General search terms*	BsAb search terms*	Infection search terms*
• Multiple myeloma • Infection • Bispecific antibodies	• Teclistamab • Elranatamab • REGN5458 • Pavurutamab • ABBV-383 • Pacanalotamab • Alnuctamab • WVT078 • Talquetamab • RG6234 • Cevostamab • ISB 1342	• Pneumocystis pneumonia • Pneumocystis jirovecii • Respiratory infection • Progressive multifocal leukoencephalopathy • Cytomegalovirus • Hepatitis • Viral reactivation • Bacterial infection • Fungal infection • COVID-19

General search terms*

BsAb search terms*

Infection search terms*

• Multiple myeloma

• Infection

• Bispecific antibodies

• Teclistamab

• Elranatamab

• REGN5458

• Pavurutamab

• ABBV-383

• Pacanalotamab

• Alnuctamab

• WVT078

• Talquetamab

• RG6234

• Cevostamab

• ISB 1342

• Pneumocystis pneumonia

• Pneumocystis jirovecii

• Respiratory infection

• Progressive multifocal leukoencephalopathy

• Cytomegalovirus

• Hepatitis

• Viral reactivation

• Bacterial infection

• Fungal infection

• COVID-19

^*Search terms included derivatives of these terms and variations in the nomenclature of therapeutic agents.